NCT06056323: An ongoing trial by Shanghai Huaota Biopharmaceutical Co., Ltd.
This trial is ongoing. It must report results 9 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06056323 |
|---|---|
| Title | A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0045 in Patients With Advanced Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 18, 2023 |
| Completion date | Sept. 19, 2025 |
| Required reporting date | Sept. 19, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |